Daily programme - 09 June 2026

This interactive session focuses on grant funding, offering participants direct access to funders and grantmakers. Each expert will give a 5-minute introduction, outlining their role, funding priorities, and perspectives on the grant-making process. A moderator will pose follow-up questions to deepen the discussion and highlight practical insights. The session then opens to the audience for an open “Ask Me Anything” Q&A, encouraging candid questions and active participation. Designed as a fully interactive format, the session includes no slides or screens, prioritizing conversation and direct engagement.

Join Atlas Antibodies for an exploration into the evolution of spatial proteomics, rooted in the 20-year legacy of the Human Protein Atlas (HPA). This symposium demonstrates how the rigorously validated primary antibodies that built the HPA are now driving advanced functional discovery in cancer research. The session will cover two key technical workflows: Atlasplex, a streamlined solution for targeted 3-5 marker multiplexing, and Molboolean, an innovative technology using rolling circle amplification to detect protein-protein interactions in situ. Attendees will learn how to bridge the gap between static tissue maps and dynamic functional insights, utilizing high-certainty reagents to characterize cellular "neighborhoods" and molecular interactions. Whether you are looking to optimize your multiplexing efficiency or investigate protein-protein complexes, this session provides a practical roadmap for turning routine IHC into high-dimensional data.

Poster and Exhibition Hall

Exhibition and Poster Hall

Poster and Exhibition Hall

This session, sponsored by biomodal, will introduce the duet cfDNA solutions as complete integrated genetic and epigenetic workflows and software. The duet cfDNA solutions unlock the broadest spectrum of biomarkers, with market leading accuracy, from a single low input cfDNA sample, enabling ultra-low LoD for the detection of ctDNA. Talks will demonstrate how, in a liquid biopsy setting, 6-base data detects cancers earlier than other methylation sequencing approaches across multiple cohorts. Additional data will show how 6-base data enables a better understanding biological mechanisms of prostate cancer treatment response than existing liquid biopsy approaches.

Dr. Wiesner will highlight how Advanced Cell Diagnostics and Lunaphore, Bio-Techne brands, are transforming the future of oncology research and precision medicine with spatial biology tools. Dr. Karen, from the Weizmann Institute of Science, will talk about how modern lung cancer treatment depends on multiple biomarkers, but current diagnostic workflows exhaust small biopsies and slow down life-saving therapy decisions. Her team developed a multiplexed imaging approach that reads dozens of markers from one tissue section, enabling comprehensive diagnosis while conserving tissue and shortening turnaround time.

(open to EACR Early Career & Student Members, pre-registration required)

Discover how 3D chromatin organization acts as a master regulator of leukemia biology, learn cutting-edge approaches to profile spatial genome architecture in cancer, and understand how linking chromatin structure to gene expression networks can identify new precision medicine strategies for improving patient outcomes. • Learn how 3D chromatin conformation capture can distinguish leukemia subtypes and pinpoint their cells of origin by mapping lineage-defining regulatory hubs. • Explore how 3D genome profiling uncovers intra‑tumor heterogeneity in T‑ALL, providing new biomarkers to anticipate and monitor therapy response. • See how chromatin interaction matrices expose structural variants and enhancer hijacking events that drive oncogene activation and leukemic transformation.

Over three decades, 3DHISTECH has advanced digital pathology through comprehensive 2D imaging solutions spanning the entire diagnostic workflow. Yet tissue is inherently three dimensional. The Pannoramic X micro CT introduces a breakthrough in 3D digital pathology by enabling ultra-high resolution imaging of intact FFPE blocks, macroblocks, and large specimens without sectioning or staining. Using soft X ray virtual slicing and staining, it preserves tissue integrity while revealing unprecedented morphological and biomarker detail. Integrated with advanced visualization and AI driven analysis, the system enhances tumor assessment, cancer staging, and research applications. The future of pathology is volumetric—unlocking deeper insight through true 3D tissue exploration.

Poster and Exhibition Hall

Recessive Dystrophic Epidermolysis Bullosa (RDEB) is a rare genetic disease associated with chronic wounds and a high risk of aggressive cutaneous squamous cell carcinoma (cSCC), for which effective treatments are lacking. This study investigates a multi-omics-driven drug repurposing strategy to identify new therapeutic options. Integrated analysis of molecular data revealed dysregulated pathways in RDEB-associated cSCC and identified statins as potential anti-tumor agents. To validate this, statins were tested in vitro using EB-derived cancer cell models. Functional assays assessing cell viability and cytotoxicity were performed using automated plate-based detection, including the Tecan Spark® Cyto, enabling reproducible and quantitative evaluation of cellular responses. Preliminary results showed reduced cancer cell viability, supporting a potential anti-tumor effect. Ongoing in vivo studies using xenograft models aim to determine whether these findings translate into tumor growth inhibition. This work highlights the potential of combining multi-omics analysis with automated functional validation to accelerate drug repurposing for rare and life-threatening diseases.

Spotlight Theatre

Poster and Exhibition Hall